Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/10/2012US8217029 Oxazolidinone antibiotics
07/10/2012US8217028 1,2,4-oxadiazole indole compounds
07/10/2012US8217027 Sphingosine-1-phosphate receptor agonist and antagonist compounds
07/10/2012US8217026 Substituted porphyrins
07/10/2012US8217025 Utilizing such as 4-fluoro-17-ethynylandrost-5-ene-3-,7-,17-triol; pulmonary conditions, hyperglycemia, type 2 diabetes, insulin resistance
07/10/2012US8217024 Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
07/10/2012US8217023 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring
07/10/2012US8217022 Analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for tumour treatment
07/10/2012US8217021 Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
07/10/2012US8217018 Reversible siRNA-based silencing of mutant and endogenous wild-type huntingtin gene and its application for the treatment of Huntington's disease
07/10/2012US8217017 Modulation of insulin like growth factor I receptor expression
07/10/2012US8217014 Pharmaceutical composition for treatment of blood clotting disorder
07/10/2012US8217013 Polyene diester antibiotics
07/10/2012US8217004 Sequestering agent for micronutrient fertilisers
07/10/2012US8217001 Modification of feeding behavior
07/10/2012US8216792 Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
07/10/2012US8216617 Tablet comprising natural allicin and method for producing the same
07/10/2012US8216614 Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
07/10/2012US8216610 Oral paracetamol formulations
07/10/2012US8216609 Release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents; a process for preparing the dosage form.
07/10/2012US8216607 Combination of ceramide and gemcitabine for inducing cell death and uses thereof in treating cancer
07/10/2012US8216604 Intranasally administering aqueous solution offentanyl or salt thereof and pectin
07/10/2012US8216599 Administering hydroxytyrosol and oleuropein in a ratio of 1:1-200:1
07/10/2012US8216584 Imaging, diagnosis and treatment of disease
07/10/2012US8216567 Therapeutic ribonucleases
07/10/2012US8216561 Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflex
07/10/2012US8216560 Administering a potassium-binding polymer of a crosslinked ion exchange polymer having acid groups and an alpha/beta electronegative group in a bead form as an oral dosage; renal insufficiency; congestive heart failure; hyperkalemia; high preferential binding capaciity; stability; nonabsorbent; nontoxic
07/10/2012US8216300 Drug delivery from electroactive molecularly imprinted polymer
07/10/2012US8216277 Spine distraction implant and method
07/10/2012CA2706832C Mevalonic acid derivatives
07/10/2012CA2698561C Hyaluronic acid oligosaccharide fractions and drugs containing the same
07/10/2012CA2644311C Composition and method for topical treatment of tar-responsive dermatological disorders
07/10/2012CA2641599C Method for improving cell permeability to foreign particles
07/10/2012CA2638081C Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
07/10/2012CA2635354C Compositions and methods for the inhibition of phospholipase a2
07/10/2012CA2609098C Novel food ingredient and products containing the same
07/10/2012CA2601955C Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
07/10/2012CA2592995C 1-thio-d-glucitol derivatives
07/10/2012CA2588415C 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
07/10/2012CA2583087C Chroman derivatives
07/10/2012CA2566461C Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
07/10/2012CA2564062C Indole derivative having piperidine ring
07/10/2012CA2563162C Dosage form containing pantoprazole as active ingredient
07/10/2012CA2562535C 2-alkylidene-18,19-dinor-vitamin d compounds
07/10/2012CA2553269C Quinoline derivatives and use thereof as mycobacterial inhibitors
07/10/2012CA2551171C Modulators of peripheral 5-ht receptors
07/10/2012CA2545942C Aryl imidazoles and their use as anti-cancer agents
07/10/2012CA2543820C Methods for synthesizing quinolinone compounds
07/10/2012CA2542909C 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
07/10/2012CA2542730C Anion-binding polymers and uses thereof
07/10/2012CA2542647C Derivatives of n-heterocyclylmethylbenzamides, prepartion method thereof and application of same in therapeutics
07/10/2012CA2540647C Tetrahydro-naphthalene and urea derivatives
07/10/2012CA2539426C Fused heterocyclic compounds
07/10/2012CA2537440C Malonamide derivatives blocking the activity of gama-secretase
07/10/2012CA2533925C Plants producing hyaluronic acid
07/10/2012CA2533881C Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors
07/10/2012CA2533749C Piperidine compounds useful as malonyl-coa decarboxylase inhibitors
07/10/2012CA2529735C Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities
07/10/2012CA2526430C Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
07/10/2012CA2520893C Process for the preparation of 1-n-(phenyl)-2-n-(phenyl)pyrrolidine-1,2-dicarboxamide derivatives and 1-(phenylcarbamoyl)pyrrolidine-2-carboxylic acid derivatives as intermediates
07/10/2012CA2519898C Oral administration of cyclic protein tyrosine kinase inhibitors
07/10/2012CA2518437C Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
07/10/2012CA2515991C Use of ace inhibitors for treatment of patients suffering from behavioral disorders
07/10/2012CA2514524C Use of arachidonic acid for normalization of infradian rhythm
07/10/2012CA2514373C N-phenylbenzamide derivatives as drugs for the treatment of copd
07/10/2012CA2513463C Gyrase inhibitors and uses thereof
07/10/2012CA2511505C Biguanide and dihydrotriazine derivatives
07/10/2012CA2507110C Carbamic acid esters with an anticholinergic action
07/10/2012CA2505195C Quinazolinones as potassium channel modulators
07/10/2012CA2503549C Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
07/10/2012CA2500387C A controlled release system containing temozolomide
07/10/2012CA2499994C Abuse-resistant pharmaceutical compositions
07/10/2012CA2498420C Lipophilic diesters of chelating agent for inhibition of enzyme activity
07/10/2012CA2498282C Calcium channel blockers
07/10/2012CA2498141C Orally administrable composition for improving skin quality
07/10/2012CA2494915C Female hormone-containing patch
07/10/2012CA2494832C Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
07/10/2012CA2486585C Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
07/10/2012CA2485253C Lipid a and other carbohydrate ligand analogs
07/10/2012CA2481369C Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
07/10/2012CA2479652C Crystalline micronisate of tiotropium bromide
07/10/2012CA2479341C Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
07/10/2012CA2475595C Method of reducing and preventing uvb-induced immunosuppression
07/10/2012CA2470427C Compositions and methods for treating heart failure
07/10/2012CA2470207C Matrix film tablet with controlled release of natural mixtures of conjugated estrogens
07/10/2012CA2466529C Solid, stabilized, prompt- and/or modified-release therapeutical systems for the oral administration of liquid active principles, excipients or foodstuffs
07/10/2012CA2462564C Methods of inhibiting metastases
07/10/2012CA2446951C Polythiourea lipid derivatives
07/10/2012CA2446356C Use of compositions for treating rosacea
07/10/2012CA2444821C Combination therapy using anti-angiogenic agents and tnfa
07/10/2012CA2444704C Synthesis and evaluation of phthalimide mimics as anti-angiogenic agents
07/10/2012CA2442053C Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters
07/10/2012CA2440010C Powder inhaler formulations
07/10/2012CA2439101C New medical uses of intercellular communication facilitating compounds
07/10/2012CA2417960C Method of using diketopiperazines and composition containing them
07/10/2012CA2417311C Crystalline alkali metal salts of lansoprazole and their production and use
07/10/2012CA2407675C Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs
07/10/2012CA2400916C Aminoadamantane derivatives as therapeutic agents
07/10/2012CA2372583C Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
07/10/2012CA2368677C Intramyocardial injection of autologous bone marrow
1 ... 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 ... 7860